Protection of mice and guinea pigs against tuberculosis induced by immunization with a single Mycobacterium tuberculosis recombinant antigen, MTB41. 2005

Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
Corixa Corporation, Seattle, WA, USA.

MTB41 is a Mycobacterium antigen that is recognized by CD4+ T cells early after experimental infection of mice with Mycobacterium tuberculosis and by PBMC from healthy PPD positive individuals. Immunization of mice with plasmid DNA encoding the MTB41 gene sequence results in the development of antigen-specific CD4+ and CD8+ T cells, and protection against challenge with virulent M. tuberculosis. In the present studies, in contrast to DNA immunization, we show, that a strong MTB41-specific CD4+ T cell response, but no MHC class I restricted cytotoxic T lymphocyte (CTL) activity is detected in the spleen cells of infected mice. Therefore, this data suggests that the induction of CD8+ T cell response to MTB41 epitopes by DNA immunization may not be relevant to protection because these epitopes are not recognized during the infectious process. We also compared the repertoire of rMTB41 epitope recognition by CD4+ T cells of M. tuberculosis-infected mice with the recognition repertoire of mice immunized with the recombinant rMTB41 protein. Both regimens of sensitization lead to the recognition of the same molecular epitope. Coincidentally, immunization with the soluble recombinant protein plus adjuvant, a regimen known to generate primarily CD4+ T cells, resulted in induction of protection comparable to BCG in two well-established animal models of tuberculosis (mice and guinea pigs).

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D009169 Mycobacterium tuberculosis A species of gram-positive, aerobic bacteria that produces TUBERCULOSIS in humans, other primates, CATTLE; DOGS; and some other animals which have contact with humans. Growth tends to be in serpentine, cordlike masses in which the bacilli show a parallel orientation. Mycobacterium tuberculosis H37Rv
D006168 Guinea Pigs A common name used for the genus Cavia. The most common species is Cavia porcellus which is the domesticated guinea pig used for pets and biomedical research. Cavia,Cavia porcellus,Guinea Pig,Pig, Guinea,Pigs, Guinea
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000939 Epitopes Sites on an antigen that interact with specific antibodies. Antigenic Determinant,Antigenic Determinants,Antigenic Specificity,Epitope,Determinant, Antigenic,Determinants, Antigenic,Specificity, Antigenic
D000942 Antigens, Bacterial Substances elaborated by bacteria that have antigenic activity. Bacterial Antigen,Bacterial Antigens,Antigen, Bacterial
D013154 Spleen An encapsulated lymphatic organ through which venous blood filters.

Related Publications

Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
December 1991, Infection and immunity,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
December 2017, Scientific reports,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
January 2018, Biology open,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
November 2021, Vaccines,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
September 2017, The Journal of infectious diseases,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
June 2012, Vaccine,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
October 1967, Diseases of the chest,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
October 2020, Scientific reports,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
April 2021, Vaccines,
Yasir A W Skeiky, and Mark R Alderson, and Pamela J Ovendale, and Yves Lobet, and Wilfried Dalemans, and Ian M Orme, and Steven G Reed, and Antonio Campos-Neto
January 2017, PloS one,
Copied contents to your clipboard!